Biopharmaceutical Third-Party Logistics Market Trends

Growth Drivers

• Rising demand for biologics and biosimilars: The increasing utilization of biologics for treating chronic diseases such as cancer, autoimmune diseases, and diabetes is a key factor boosting market growth. This has resulted in a growing need for sophisticated logistics solutions to handle multifaceted requirements such as navigation of distribution requirements, temperature-controlled storage, and timely transportation. According to experts at Research Nester, the biosimilars market model is set to continue its growth, doubling in size to more than USD 35 billion by 2025 and over USD 63 billion by the end of 2030.
• Increasing frequency of chronic diseases: The rising incidence of different types of chronic diseases is a key factor boosting market growth. The constant demand for coordinated care and precision medication delivery drives innovation and leads to an increase in research and development activities in the market. It has also intensified the development of conducive treatment solutions to ensure temperature-controlled transportation and high-value services.  Moreover, specialized logistic providers with equally intricate supply chains maintain product integrity to propel market growth.  

Challenges

• Integration of technology: The main challenge to the biopharmaceuticals third-party logistics market is the integration of advanced technologies such as IoT sensors, blockchain, and data analytics. The incorporation requires investments in infrastructure, gathering resources, and training people. Moreover, the process of integration also creates technical challenges such as breaches of data and lack of security thus causing complexities in delivering expertise. Thus, as technology is advancing, it is becoming increasingly complex to attain an efficient and secure market.
• Capacity constraints: The lack of cold chain logistics and transportation capacity raises immense challenges to any biopharmaceutical third-party logistics market. The increasing demand for biologics and biosimilars is comparatively much higher than the capacity provided. Cold chain storage, refrigerated vehicles, and skilled personnel to handle high-value biologics are under-supplied, which creates a bottleneck in the supply chain, causing delay, damage, and increased costs. Lack of standardization in equipment and facilities further limits the flexibility and adaptability of logistics providers to respond to changing market conditions thus impacting the capacity in the biopharmaceutical supply chain.